Altimmune, Inc.
ALT · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.28 | 0.82 | 0.40 | -0.17 |
| FCF Yield | -15.60% | -12.66% | -8.12% | -23.94% |
| EV / EBITDA | -5.03 | -5.28 | -7.84 | -1.96 |
| Quality | ||||
| ROIC | -79.91% | -48.09% | -45.88% | -47.66% |
| Gross Margin | 100.00% | -11.97% | 835.29% | -1,574.40% |
| Cash Conversion Ratio | 0.84 | 0.86 | 0.74 | 0.81 |
| Growth | ||||
| Revenue 3-Year CAGR | – | -54.12% | – | -8.74% |
| Free Cash Flow Growth | -5.26% | -20.96% | 30.74% | -161.34% |
| Safety | ||||
| Net Debt / EBITDA | 0.37 | 1.53 | 1.30 | 1.96 |
| Interest Coverage | -11,463.56 | -2,740.83 | -10,967.50 | -19,382.80 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 14.71 | 0.00 |
| Cash Conversion Cycle | 56,561.66 | 2,574.12 | -17,121.29 | 473.22 |